Analyst firms · Raymond James · KRRO
Raymond James KRRO price target and rating history
Korro Bio Inc. (KRRO) · Health Care
Raymond James rates Korro Bio Inc. (KRRO) Outperform with a $23 price target, as of its latest action on Mar 13, 2026. It has published 3 rating actions on KRRO since October 2024, including 1 upgrade and 1 downgrade. Across 7 firms with a KRRO price target in the last 12 months, the median target is $21. Raymond James's $23 is 10% above that.
- Current rating
- Outperform
- Price target
- $23
- Median target, all firms
- $21
- Actions on KRRO
- 3
Raymond James price target on KRRO
Every Raymond James rating on KRRO
- Mar 13, 2026
- Nov 13, 2025
- Oct 21, 2024
How other firms rate KRRO
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Citigroup | Buy | $21 | May 18, 2026 |
| Raymond James | Outperform | $23 | Mar 13, 2026 |
| William Blair | Outperform | Feb 17, 2026 | |
| Piper Sandler | Overweight | $30 | Jan 29, 2026 |
| Chardan Capital Markets | Buy | $15 | Jan 29, 2026 |
| H.C. Wainwright | Buy | $20 | Jan 29, 2026 |
| Cantor Fitzgerald | Overweight | $21 | Jan 28, 2026 |
| Oppenheimer | Outperform | $22 | Jan 28, 2026 |
Questions about Raymond James and KRRO
- What is Raymond James's price target for KRRO?
- Raymond James's latest stated price target for Korro Bio Inc. (KRRO) is $23, from its action on Mar 13, 2026.
- What is Raymond James's rating on KRRO?
- Raymond James rates KRRO Outperform, a bullish rating, as of Mar 13, 2026.
- When did Raymond James last change its view on KRRO?
- On Mar 13, 2026, Raymond James upgrades to Outperform from Mkt Perform, price target $23.
- How does Raymond James's KRRO target compare with other analysts?
- Across 7 firms with a KRRO price target in the last 12 months, the median target is $21. Raymond James's $23 is 10% above that.
More KRRO rating histories
All Raymond James ratingsKRRO news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.